Wei Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wei Mao has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ji Zhu
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
5 shared publications Qianping Chen
Department of Abdominal Radiotherapy Zhejiang Cancer Hospital Hangzhou 310022 P. R. China
4 shared publicationsDong Liu
Department of Abdominal Radiotherapy Zhejiang Cancer Hospital Hangzhou 310022 P. R. China
3 shared publicationsQingyu Jiang
Department of Abdominal Radiotherapy Zhejiang Cancer Hospital Hangzhou 310022 P. R. China
3 shared publicationsQuanquan Sun
Department of Abdominal Radiotherapy Zhejiang Cancer Hospital Hangzhou 310022 P. R. China
3 shared publications- Jia-Da Li
Furong Laboratory, Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, P. R. China
2 shared publications
Latest Publications
- Open Access
- 11 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (37) , e07080
Patients‐Derived Organoids Sequencing‐based FOXP4 Facilitates Radioresistance by Transcriptionally Modifying GPX4 to Regulate ferroptosis in Colorectal Cancer
More than 50% of patients with colorectal cancer (CRC) exhibit radioresistance, indicating the need for further research on the disease. Therefore, the aim of this study is to identify radioresistance genes and elucidate the underlying molecular mechanisms using patient‐derived organoids (PDOs). Transcriptome analyses are performed on radio‐resistant and ‐sensitive PDOs, CRC cells, and xenograft tissues to screen for radioresistant genes. Additionally, the genetic homology between PDOs and clinical tissues is verified using whole‐exome sequencing. Functional experiments are performed to validate the roles of the candidate genes using cellular, organoid, and animal models. Forkhead box P4 (FOXP4) is identified as a differentially expressed genes between the radio‐sensitive and ‐resistant groups that is linked to radioresistance. Further experiments show that FOXP4 promoted radioresistance by suppressing ferroptosis. Mechanistically, FOXP4 regulated GPX4 transcription by binding to the promoter region of GPX4 via the forkhead domain to inhibit the onset of ferroptosis. Doxorubicin (DOX) inhibited FOXP4 expression by promoting its ubiquitination and degradation, eventually increasing radiosensitivity. Notably, DOX combined with irradiation attenuated the compensatory increase in FOXP4 expression and increased radiotherapy efficacy. Conclusively, the combination therapy provides a new strategy for enhancing therapeutic efficacy in CRC.
- 11 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (37) , e07080
Open AccessPatients‐Derived Organoids Sequencing‐based FOXP4 Facilitates Radioresistance by Transcriptionally Modifying GPX4 to Regulate ferroptosis in Colorectal Cancer
More than 50% of patients with colorectal cancer (CRC) exhibit radioresistance, indicating the need for further research on the disease. Therefore, the aim of this study is to identify radioresistance genes and elucidate the underlying molecular mechanisms using patient‐derived organoids (PDOs). Transcriptome analyses are performed on radio‐resistant and ‐sensitive PDOs, CRC cells, and xenograft tissues to screen for radioresistant genes. Additionally, the genetic homology between PDOs and clinical tissues is verified using whole‐exome sequencing. Functional experiments are performed to validate the roles of the candidate genes using cellular, organoid, and animal models. Forkhead box P4 (FOXP4) is identified as a differentially expressed genes between the radio‐sensitive and ‐resistant groups that is linked to radioresistance. Further experiments show that FOXP4 promoted radioresistance by suppressing ferroptosis. Mechanistically, FOXP4 regulated GPX4 transcription by binding to the promoter region of GPX4 via the forkhead domain to inhibit the onset of ferroptosis. Doxorubicin (DOX) inhibited FOXP4 expression by promoting its ubiquitination and degradation, eventually increasing radiosensitivity. Notably, DOX combined with irradiation attenuated the compensatory increase in FOXP4 expression and increased radiotherapy efficacy. Conclusively, the combination therapy provides a new strategy for enhancing therapeutic efficacy in CRC.
- Open Access
- 18 February 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (6) , 1301-1312
NADPH oxidase activator 1 (NOXA1) suppresses ferroptosis and radiosensitization in colorectal cancer
Radiotherapy is one of the main treatments for colorectal cancer (CRC), but due to the intrinsic resistance of cells or resistance caused by long-term radiotherapy, the effectiveness of this treatment is limited for some CRC patients. Consequently, identifying novel sensitization strategies is essential. This study identifies Noxa1 as a marker linked to radiotherapy resistance in CRC, suggesting its potential as a prognostic biomarker for patients with CRC. The study found that Noxa1 was significantly overexpressed in radiotherapy-resistant colorectal cancer patients, correlating with a poor prognosis. Additionally, we discovered that the high expression of Noxa1 was negatively correlated with ferroptosis and primarily played a role through the glutathione metabolic pathway, as indicated by GSVA analysis. Experimental data indicated that the expression levels of NOXA1, SLC7A11, and GPX4 were significantly elevated in CRC cell lines resistant to radiotherapy. The expression of SLC7A11 and GPX4 decreased after the knockdown of Noxa1, leading to an increase in cellular ROS levels, which induced ferroptosis and sensitized the cells to radiotherapy. Therefore, Noxa1 might influence the radiotherapy sensitivity of CRC via regulating ferroptosis. Targeting Noxa1 could enhance radiotherapy sensitization and improve the prognosis of CRC patients.
- 18 February 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (6) , 1301-1312
Open AccessNADPH oxidase activator 1 (NOXA1) suppresses ferroptosis and radiosensitization in colorectal cancer
Radiotherapy is one of the main treatments for colorectal cancer (CRC), but due to the intrinsic resistance of cells or resistance caused by long-term radiotherapy, the effectiveness of this treatment is limited for some CRC patients. Consequently, identifying novel sensitization strategies is essential. This study identifies Noxa1 as a marker linked to radiotherapy resistance in CRC, suggesting its potential as a prognostic biomarker for patients with CRC. The study found that Noxa1 was significantly overexpressed in radiotherapy-resistant colorectal cancer patients, correlating with a poor prognosis. Additionally, we discovered that the high expression of Noxa1 was negatively correlated with ferroptosis and primarily played a role through the glutathione metabolic pathway, as indicated by GSVA analysis. Experimental data indicated that the expression levels of NOXA1, SLC7A11, and GPX4 were significantly elevated in CRC cell lines resistant to radiotherapy. The expression of SLC7A11 and GPX4 decreased after the knockdown of Noxa1, leading to an increase in cellular ROS levels, which induced ferroptosis and sensitized the cells to radiotherapy. Therefore, Noxa1 might influence the radiotherapy sensitivity of CRC via regulating ferroptosis. Targeting Noxa1 could enhance radiotherapy sensitization and improve the prognosis of CRC patients.
- 15 February 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 209, 104658
The role of cGAS-STING in remodeling the tumor immune microenvironment induced by radiotherapy
- 15 February 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 209, 104658
The role of cGAS-STING in remodeling the tumor immune microenvironment induced by radiotherapy
- Open Access
Epigenetic Mechanisms in the Transcriptional Regulation of Circadian Rhythm in Mammals
Almost all organisms, from the simplest bacteria to advanced mammals, have a near 24 h circadian rhythm. Circadian rhythms are highly conserved across different life forms and are regulated by circadian genes as well as by related transcription factors. Transcription factors are fundamental to circadian rhythms, influencing gene expression, behavior in plants and animals, and human diseases. This review examines the foundational research on transcriptional regulation of circadian rhythms, emphasizing histone modifications, chromatin remodeling, and Pol II pausing control. These studies have enhanced our understanding of transcriptional regulation within biological circadian rhythms and the importance of circadian biology in human health. Finally, we summarize the progress and challenges in these three areas of regulation to move the field forward.
Open AccessEpigenetic Mechanisms in the Transcriptional Regulation of Circadian Rhythm in Mammals
Almost all organisms, from the simplest bacteria to advanced mammals, have a near 24 h circadian rhythm. Circadian rhythms are highly conserved across different life forms and are regulated by circadian genes as well as by related transcription factors. Transcription factors are fundamental to circadian rhythms, influencing gene expression, behavior in plants and animals, and human diseases. This review examines the foundational research on transcriptional regulation of circadian rhythms, emphasizing histone modifications, chromatin remodeling, and Pol II pausing control. These studies have enhanced our understanding of transcriptional regulation within biological circadian rhythms and the importance of circadian biology in human health. Finally, we summarize the progress and challenges in these three areas of regulation to move the field forward.
- Open Access
- 13 November 2024
- Published by Elsevier in Translational Oncology
- Vol. 51, 102190
Combining methylated RNF180 and SFRP2 plasma biomarkers for noninvasive diagnosis of gastric cancer
- 13 November 2024
- Published by Elsevier in Translational Oncology
- Vol. 51, 102190
Open AccessCombining methylated RNF180 and SFRP2 plasma biomarkers for noninvasive diagnosis of gastric cancer
- Open Access
- 1 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10665
RORα Suppresses Cancer-Associated Inflammation by Repressing Respiratory Complex I-Dependent ROS Generation
Breast cancer development is associated with macrophage infiltration and differentiation in the tumor microenvironment. Our previous study highlights the crucial function of reactive oxygen species (ROS) in enhancing macrophage infiltration during the disruption of mammary tissue polarity. However, the regulation of ROS and ROS-associated macrophage infiltration in breast cancer has not been fully determined. Previous studies identified retinoid orphan nuclear receptor alpha (RORα) as a potential tumor suppressor in human breast cancer. In the present study, we showed that retinoid orphan nuclear receptor alpha (RORα) significantly decreased ROS levels and inhibited ROS-mediated cytokine expression in breast cancer cells. RORα expression in mammary epithelial cells inhibited macrophage infiltration by repressing ROS generation in the co-culture assay. Using gene co-expression and chromatin immunoprecipitation (ChIP) analyses, we identified complex I subunits NDUFS6 and NDUFA11 as RORα targets that mediated its function in suppressing superoxide generation in mitochondria. Notably, the expression of RORα in 4T1 cells significantly inhibited cancer metastasis, reduced macrophage accumulation, and enhanced M1-like macrophage differentiation in tumor tissue. In addition, reduced RORα expression in breast cancer tissue was associated with an increased incidence of cancer metastasis. These results provide additional insights into cancer-associated inflammation, and identify RORα as a potential target to suppress ROS-induced mammary tumor progression.
- 1 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10665
Open AccessRORα Suppresses Cancer-Associated Inflammation by Repressing Respiratory Complex I-Dependent ROS Generation
Breast cancer development is associated with macrophage infiltration and differentiation in the tumor microenvironment. Our previous study highlights the crucial function of reactive oxygen species (ROS) in enhancing macrophage infiltration during the disruption of mammary tissue polarity. However, the regulation of ROS and ROS-associated macrophage infiltration in breast cancer has not been fully determined. Previous studies identified retinoid orphan nuclear receptor alpha (RORα) as a potential tumor suppressor in human breast cancer. In the present study, we showed that retinoid orphan nuclear receptor alpha (RORα) significantly decreased ROS levels and inhibited ROS-mediated cytokine expression in breast cancer cells. RORα expression in mammary epithelial cells inhibited macrophage infiltration by repressing ROS generation in the co-culture assay. Using gene co-expression and chromatin immunoprecipitation (ChIP) analyses, we identified complex I subunits NDUFS6 and NDUFA11 as RORα targets that mediated its function in suppressing superoxide generation in mitochondria. Notably, the expression of RORα in 4T1 cells significantly inhibited cancer metastasis, reduced macrophage accumulation, and enhanced M1-like macrophage differentiation in tumor tissue. In addition, reduced RORα expression in breast cancer tissue was associated with an increased incidence of cancer metastasis. These results provide additional insights into cancer-associated inflammation, and identify RORα as a potential target to suppress ROS-induced mammary tumor progression.